Kadeflora (Lactobacillus Plantarum P 17630)

The Lactobacillus plantarum strain in Kadeflora colonises the vaginal epithelium and ferments glycogen to produce lactic acid, which lowers the vaginal pH. The acidic environment suppresses pathogenic bacteria and yeast, while the strain also releases bacteriocins and hydrogen peroxide that directly inhibit harmful microorganisms, helping to re‑establish a balanced flora.

The dosage of Kadeflora is determined by the prescribing healthcare professional based on the individual’s condition and treatment plan. Specific dosing instructions, frequency, and duration should be obtained from the prescriber and are not provided here.

Safety data for Kadeflora in pregnancy and lactation are limited. Women who are pregnant or breastfeeding should discuss potential benefits and risks with their obstetrician or healthcare provider before initiating therapy.

To order Kadeflora, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Kadeflora contains the specific strain Lactobacillus plantarum P 17630, which is known for strong acid‑producing and bacteriocin‑secreting properties. Compared with other probiotic strains such as Lactobacillus rhamnosus or Lactobacillus reuteri, plantarum may offer a broader antimicrobial spectrum, though clinical outcomes can vary and should be evaluated by a clinician.

Kadeflora should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain bacterial viability throughout its shelf life.

Kadeflora is administered intravaginally. The product is typically inserted into the vagina using the supplied applicator or as directed by a healthcare professional. Administration should be performed in a clean environment, following the prescriber’s instructions regarding timing and frequency.

The most serious risks include rare allergic reactions such as rash, swelling, or anaphylaxis, and the potential for systemic infection (bacteremia) in severely immunocompromised individuals. Any signs of severe infection or allergic response should prompt immediate medical evaluation.

Kadeflora should be avoided by individuals with known hypersensitivity to Lactobacillus plantarum or any excipients in the formulation. It is also contraindicated in patients with severe immunosuppression unless specifically advised by a physician, and it should not be used without medical guidance during pregnancy or lactation.